{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:26:13Z","timestamp":1774020373804,"version":"3.50.1"},"reference-count":67,"publisher":"Bentham Science Publishers Ltd.","issue":"2","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPR"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Acute lymphoblastic leukemia is the most frequent pediatric malignancy in children, comprising 30% of all pediatric malignancies; adult ALL comprises 5% of all ALL cases, which have a 186.6 per 1 million incidence. In pediatric ALL (pALL), on which this review focuses, ap-proximately 1 in 285 children are diagnosed with cancer before the age of 20, and approximately 1 in 530 young adults between the ages of 20 and 39 years old is a childhood cancer survivor. The survival probability in pALL is now very high, approximately 80-90%. Thus, the most important is to improve supportive care and treatment based on relapse risk, optimally being based on the genet-ic feature of malignant cells. Improvements made by now are mainly the classifying of subgroups based on genetic characteristics such as aneuploidy or translocation and aligning them with treat-ment response. Relevant genetic changes in ALL pathogenesis are transcription regulators of lym-phoid development (PAX5, IKZF1, EBF1, and LEF1) and\/or coactivators (TBL1XR1 and ERG), lymphoid signaling (BTLA, and CD200 TOX), and tumor suppressor genes (CDKN2A, CDKN2B, RB1, and TP53). This review aims to summarize treatment strategies inhibiting tyrosine kinases, in-fluencing different signaling pathways, BCL inhibitors, and anti-CD therapy (anti-cluster differenti-ation therapy) in pALL. CAR T-cell therapy (chimeric antigen receptors T-cell therapy) is under re-search and requires further development.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573396318666220901165247","type":"journal-article","created":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T12:45:26Z","timestamp":1662209126000},"page":"150-156","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Targeted Treatment and Immunotherapy in High-risk and Relapsed\/\nRefractory Pediatric Acute Lymphoblastic Leukemia"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4807-2938","authenticated-orcid":true,"given":"Gazmend","family":"Temaj","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, UBT College, Prishtina, Kosovo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Violeta","family":"Graiqevci-Uka","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Clinical Center, Prishtina, Kosovo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emir","family":"Behluli","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Clinical Center, Prishtina, Kosovo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidvana","family":"Spahiu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Clinical Center, Prishtina, Kosovo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Liehr","sequence":"additional","affiliation":[{"name":"Jena University Hospital, Friedrich Schiller\nUniversity, Institute of Human Genetics, Jena, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3322\/caac.21219","volume":"64","author":"Ward E.","year":"2014","unstructured":"Ward E.; DeSantis C.; Robbins A.; Kohler B.; Jemal A.; Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014,64(2),83-103","journal-title":"CA Cancer J Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1038\/leu.2014.142","volume":"28","author":"Pui C.H.","year":"2014","unstructured":"Pui C.H.; Pei D.; Campana D.; A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia 2014,28(12),2336-2343","journal-title":"Leukemia"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1182\/blood-2002-12-3817","volume":"102","author":"Greaves M.F.","year":"2003","unstructured":"Greaves M.F.; Maia A.T.; Wiemels J.L.; Ford A.M.; Leukemia in twins: Lessons in natural history. Blood 2003,102(7),2321-2333","journal-title":"Blood"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/MPH.0b013e31828f8746","volume":"35","author":"Lo Nigro L.","year":"2013","unstructured":"Lo Nigro L.; Biology of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2013,35(4),245-252","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1182\/asheducation.V2012.1.389.3798360","volume":"2012","author":"Mullighan C.G.","year":"2012","unstructured":"Mullighan C.G.; The molecular genetic makeup of acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program) 2012,2012(1),389-396","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3324\/haematol.2016.151035","volume":"102","author":"Hirabayashi S.","year":"2017","unstructured":"Hirabayashi S.; Ohki K.; Nakabayashi K.; ZNF384 -related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype. Haematologica 2017,102(1),118-129","journal-title":"Haematologica"},{"key":"ref=7a","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","volume":"105","author":"Inaba H.","year":"2020","unstructured":"Inaba H.; Mullighan C.G.; Pediatric acute lymphoblastic leukemia. Haematologica 2020,105(11),2524-2539","journal-title":"Haematologica"},{"key":"ref=7b","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.3390\/jcm10091926","volume":"10","author":"Inaba H.","year":"2021","unstructured":"Inaba H.; Pui C.H.; Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia. J Clin Med 2021,10(9),1926","journal-title":"J Clin Med"},{"key":"ref=8","first-page":"4036","volume":"94","author":"Heerema N.A.","year":"1999","unstructured":"Heerema N.A.; Nachman J.B.; Sather H.N.; Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: A report from the children\u2019s cancer group. Blood 1999,94(12),4036-4045","journal-title":"Blood"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1200\/JCO.1998.16.2.527","volume":"16","author":"Uckun F.M.","year":"1998","unstructured":"Uckun F.M.; Sensel M.G.; Sather H.N.; Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: A report from the children\u2019s cancer group. J Clin Oncol 1998,16(2),527-535","journal-title":"J Clin Oncol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(02)08782-2","volume":"359","author":"Pui C.H.","year":"2002","unstructured":"Pui C.H.; Gaynon P.S.; Boyett J.M.; Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002,359(9321),1909-1915","journal-title":"Lancet"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1182\/blood.V86.11.4263.bloodjournal86114263","volume":"86","author":"Romana S.P.","year":"1995","unstructured":"Romana S.P.; Poirel H.; Leconiat M.; High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 1995,86(11),4263-4269","journal-title":"Blood"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1182\/blood.V94.1.374.413a48c_374_376","volume":"94","author":"Seeger K.","year":"1999","unstructured":"Seeger K.; Buchwald D.; Peter A.; TEL-AML1 fusion in relapsed childhood acute lymphoblastic leukemia. Blood 1999,94(1),374-376","journal-title":"Blood"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.1182\/blood.V92.12.4792","volume":"92","author":"Loh M.L.","year":"1998","unstructured":"Loh M.L.; Silverman L.B.; Young M.L.; Incidence of TEL\/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood 1998,92(12),4792-4797","journal-title":"Blood"},{"key":"ref=14","first-page":"213","volume":"52","author":"Kar Y.D.","year":"2017","unstructured":"Kar Y.D.; &#xD6;zdemir Z.C.; B&#xF6;r &#xD6;.; Evaluation of febrile neutropenic attacks of pediatric hematology-oncology patients. Turk Pediatri Ars 2017,52(4),213-220","journal-title":"Turk Pediatri Ars"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"e28543","DOI":"10.1002\/pbc.28543","volume":"67","author":"Slayton W.B.","year":"2020","unstructured":"Slayton W.B.; Schultz K.R.; Silverman L.B.; Hunger S.P.; How we approach Philadelphia chromosome\u2010positive acute lymphoblastic leukemia in children and young adults. Pediatr Blood Cancer 2020,67(10),e28543","journal-title":"Pediatr Blood Cancer"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1182\/blood-2017-06-743252","volume":"130","author":"Tasian S.K.","year":"2017","unstructured":"Tasian S.K.; Loh M.L.; Hunger S.P.; Philadelphia chromosome-like acute lymphoblastic leukemia. Blood 2017,130(19),2064-2072","journal-title":"Blood"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1182\/blood.2019001244","volume":"134","author":"Tanasi I.","year":"2019","unstructured":"Tanasi I.; Ba I.; Sirvent N.; Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. Blood 2019,134(16),1351-1355","journal-title":"Blood"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","volume":"11","author":"Kapoor I.","year":"2020","unstructured":"Kapoor I.; Bodo J.; Hill B.T.; Hsi E.D.; Almasan A.; Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. Cell Death Dis 2020,11(11),941","journal-title":"Cell Death Dis"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1182\/blood-2019-129805","volume":"134","author":"Karol S.E.","year":"2019","unstructured":"Karol S.E.; Cooper T.M.; Bittencourt H.; Safety, efficacy, and PK of the BCL2 inhibitor venetoclax in combination with chemotherapy in pediatric and young adult patients with relapsed\/refractory acute myeloid leukemia and acute lymphoblastic leukemia: Phase 1 study. Blood 2019,134(Suppl. 1),2649","journal-title":"Blood"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"Pullarkat V.A.","year":"2021","unstructured":"Pullarkat V.A.; Lacayo N.J.; Jabbour E.; Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov 2021,11(6),1440-1453","journal-title":"Cancer Discov"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00280-005-0135-z","volume":"58","author":"Horton T.M.","year":"2006","unstructured":"Horton T.M.; Gannavarapu A.; Blaney S.M.; D\u2019Argenio D.Z.; Plon S.E.; Berg S.L.; Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol 2006,58(1),13-23","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2012-04-418640","volume":"120","author":"Messinger Y.H.","year":"2012","unstructured":"Messinger Y.H.; Gaynon P.S.; Sposto R.; Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances In Childhood Leukemia","journal-title":"Blood"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood-2020-134730","volume":"136","author":"Teachey D.T.","year":"2020","unstructured":"Teachey D.T.; Devidas M.; Wood B.L.; Cranial radiation can be eliminated in most children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and bortezomib potentially improves survival in children with T-cell Lymphoblastic Lymphoma (T-LL): Results of Children\u2019s Oncology Group (COG) trial AALL1231. Blood 2020,136(Suppl. 1),11-12","journal-title":"Blood"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1182\/blood-2009-02-206722","volume":"114","author":"Gutierrez A.","year":"2009","unstructured":"Gutierrez A.; Sanda T.; Grebliunaite R.; High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 2009,114(3),647-650","journal-title":"Blood"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1182\/blood-2005-05-1935","volume":"107","author":"Teachey D.T.","year":"2006","unstructured":"Teachey D.T.; Obzut D.A.; Cooperman J.; The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 2006,107(3),1149-1155","journal-title":"Blood"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ccr.2006.09.006","volume":"10","author":"Wei G.","year":"2006","unstructured":"Wei G.; Twomey D.; Lamb J.; Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006,10(4),331-342","journal-title":"Cancer Cell"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1182\/blood-2008-02-137752","volume":"113","author":"Crazzolara R.","year":"2009","unstructured":"Crazzolara R.; Cisterne A.; Thien M.; Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. Blood 2009,113(14),3297-3306","journal-title":"Blood"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1182\/blood-2005-03-0929","volume":"106","author":"Avellino R.","year":"2005","unstructured":"Avellino R.; Romano S.; Parasole R.; Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 2005,106(4),1400-1406","journal-title":"Blood"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"e27062","DOI":"10.1002\/pbc.27062","volume":"65","author":"Place A.E.","year":"2018","unstructured":"Place A.E.; Pikman Y.; Stevenson K.E.; Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2018,65(7),e27062","journal-title":"Pediatr Blood Cancer"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.beha.2018.10.001","volume":"31","author":"Ferrando A.","year":"2018","unstructured":"Ferrando A.; Can one target T-cell all? Best Pract Res Clin Haematol 2018,31(4),361-366","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood-2016-10-706465","volume":"129","author":"Girardi T.","year":"2017","unstructured":"Girardi T.; Vicente C.; Cools J.; De Keersmaecker K.; The genetics and molecular biology of T-ALL. Blood 2017,129(9),1113-1123","journal-title":"Blood"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11899-019-00501-3","volume":"14","author":"McMahon C.M.","year":"2019","unstructured":"McMahon C.M.; Luger S.M.; Relapsed T.; Relapsed T cell all: Current approaches and new directions. Curr Hematol Malig Rep 2019,14(2),83-93","journal-title":"Curr Hematol Malig Rep"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nrc.2016.63","volume":"16","author":"Belver L.","year":"2016","unstructured":"Belver L.; Ferrando A.; The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer 2016,16(8),494-507","journal-title":"Nat Rev Cancer"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.3390\/ijms18091904","volume":"18","author":"Bongiovanni D.","year":"2017","unstructured":"Bongiovanni D.; Saccomani V.; Piovan E.; Aberrant signaling pathways in T-cell acute lymphoblastic leukemia. Int J Mol Sci 2017,18(9),1904","journal-title":"Int J Mol Sci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood-2014-06-580480","volume":"125","author":"Maude S.L.","year":"2015","unstructured":"Maude S.L.; Dolai S.; Delgado-Martin C.; Efficacy of JAK\/STAT pathway inhibition in murine xenograft models of Early T-Cell Precursor (ETP) acute lymphoblastic leukemia. Blood 2015,125(11),1759-1767","journal-title":"Blood"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10555-019-09834-0","volume":"38","author":"Inaba H.","year":"2019","unstructured":"Inaba H.; Pui C.H.; Immunotherapy in pediatric acute lymphoblastic leukemia. Cancer Metastasis Rev 2019,38(4),595-610","journal-title":"Cancer Metastasis Rev"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"Kantarjian H.","year":"2017","unstructured":"Kantarjian H.; Stein A.; G&#xF6;kbuget N.; Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 2017,376(9),836-847","journal-title":"N Engl J Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"G&#xF6;kbuget N.","year":"2018","unstructured":"G&#xF6;kbuget N.; Dombret H.; Bonifacio M.; Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 2018,131(14),1522-1531","journal-title":"Blood"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jama.2021.0669","volume":"325","author":"Brown P.A.","year":"2021","unstructured":"Brown P.A.; Ji L.; Xu X.; Effect of post-reinduction therapy consolidation with blinatumomab vs. chemotherapy on disease-free survival in children, adolescents, and young adults with the first relapse of B-cell acute lymphoblastic leukemia: A randomized clinical trial. JAMA 2021,325(9),833-842","journal-title":"JAMA"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2021.0987","volume":"325","author":"Locatelli F.","year":"2021","unstructured":"Locatelli F.; Zugmaier G.; Rizzari C.; Effect of blinatumomab vs. chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: A randomized clinical trial. JAMA 2021,325(9),843-854","journal-title":"JAMA"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2147\/PROM.S149420","volume":"9","author":"Hathaway L.","year":"2018","unstructured":"Hathaway L.; Sen J.M.; Keng M.; Impact of blinatumomab on patient outcomes in relapsed\/refractory acute lymphoblastic leukemia: Evidence to date. Patient Relat Outcome Meas 2018,9,329-337","journal-title":"Patient Relat Outcome Meas"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/ajh.24783","volume":"92","author":"Aldoss I.","year":"2017","unstructured":"Aldoss I.; Song J.; Stiller T.; Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia. Am J Hematol 2017,92(9),858-865","journal-title":"Am J Hematol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-015-0213-6","volume":"8","author":"K&#xF6;hnke T.","year":"2015","unstructured":"K&#xF6;hnke T.; Krupka C.; Tischer J.; Kn&#xF6;sel T.; Subklewe M.; Increase of PD-L1 expressing B-precursor all cells in a patient resistant to the CD19\/CD3-bispecific T cell engager antibody blinatumomab. J Hematol Oncol 2015,8(1),111","journal-title":"J Hematol Oncol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","volume":"129","author":"Braig F.","year":"2017","unstructured":"Braig F.; Brandt A.; Goebeler M.; Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood 2017,129(1),100-104","journal-title":"Blood"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"Orlando E.J.","year":"2018","unstructured":"Orlando E.J.; Han X.; Tribouley C.; Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med 2018,24(10),1504-1506","journal-title":"Nat Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"Sotillo E.","year":"2015","unstructured":"Sotillo E.; Barrett D.M.; Black K.L.; Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 2015,5(12),1282-1295","journal-title":"Cancer Discov"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","volume":"131","author":"Bride K.L.","year":"2018","unstructured":"Bride K.L.; Vincent T.L.; Im S.Y.; Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood 2018,131(9),995-999","journal-title":"Blood"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11864-020-0712-8","volume":"21","author":"Hodby K.A.","year":"2020","unstructured":"Hodby K.A.; Marks D.I.; Recent advances in the management of acute lymphoblastic leukaemia. Curr Treat Options Oncol 2020,21(3),23","journal-title":"Curr Treat Options Oncol"},{"key":"ref=49","first-page":"djv439","volume":"108","author":"Dai H","year":"2016","unstructured":"Dai H; Wang Y; Lu X; Han W; Chimeric antigen receptors modified T-cells for cancer therapy. Natl Cancer Inst 2016,108(7),djv439","journal-title":"Natl Cancer Inst"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"Maude S.L.","year":"2018","unstructured":"Maude S.L.; Laetsch T.W.; Buechner J.; Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018,378(5),439-448","journal-title":"N Engl J Med"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","volume":"20","author":"Maude S.L.","year":"2014","unstructured":"Maude S.L.; Barrett D.; Teachey D.T.; Grupp S.A.; Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 2014,20(2),119-122","journal-title":"Cancer J"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"Lee D.W.","year":"2014","unstructured":"Lee D.W.; Gardner R.; Porter D.L.; Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014,124(2),188-195","journal-title":"Blood"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1200\/JCO.20.02477","volume":"39","author":"Kadauke S.","year":"2021","unstructured":"Kadauke S.; Myers R.M.; Li Y.; Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: A prospective clinical trial. J Clin Oncol 2021,39(8),920-930","journal-title":"J Clin Oncol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood.2019004000","volume":"136","author":"Hill J.A.","year":"2020","unstructured":"Hill J.A.; Seo S.K.; How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood 2020,136(8),925-935","journal-title":"Blood"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","volume":"121","author":"Haso W.","year":"2013","unstructured":"Haso W.; Lee D.W.; Shah N.N.; Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 2013,121(7),1165-1174","journal-title":"Blood"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","volume":"16","author":"Shah N.N.","year":"2019","unstructured":"Shah N.N.; Fry T.J.; Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol 2019,16(6),372-385","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"Majzner R.G.","year":"2018","unstructured":"Majzner R.G.; Mackall C.L.; Tumor antigen escapes from CAR T-cell therapy. Cancer Discov 2018,8(10),1219-1226","journal-title":"Cancer Discov"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"Fry T.J.","year":"2018","unstructured":"Fry T.J.; Shah N.N.; Orentas R.J.; CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 2018,24(1),20-28","journal-title":"Nat Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1182\/blood-2014-11-612903","volume":"126","author":"Qin H.","year":"2015","unstructured":"Qin H.; Cho M.; Haso W.; Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood 2015,126(5),629-639","journal-title":"Blood"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1182\/blood-2019-129411","volume":"134","author":"Schultz L.M.","year":"2019","unstructured":"Schultz L.M.; Muffly L.S.; Spiegel J.Y.; Phase I trial using CD19\/CD22 bispecific CAR T cells in pediatric and adult Acute Lymphoblastic Leukemia (ALL). Blood 2019,134(Suppl. 1),744","journal-title":"Blood"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood.2019000017","volume":"135","author":"Wang N.","year":"2020","unstructured":"Wang N.; Hu X.; Cao W.; Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies. Blood 2020,135(1),17-27","journal-title":"Blood"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1182\/blood.2019003293","volume":"135","author":"Pan J.","year":"2020","unstructured":"Pan J.; Zuo S.; Deng B.; Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL. Blood 2020,135(5),387-391","journal-title":"Blood"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"Kantarjian H.M.","year":"2016","unstructured":"Kantarjian H.M.; DeAngelo D.J.; Stelljes M.; Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 2016,375(8),740-753","journal-title":"N Engl J Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","volume":"53","author":"Kebriaei P.","year":"2018","unstructured":"Kebriaei P.; Cutler C.; De Lima M.; Management of important adverse events associated with inotuzumab ozogamicin: Expert panel review. Bone Marrow Transplant 2018,53(4),449-456","journal-title":"Bone Marrow Transplant"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1182\/blood.2020007848","volume":"137","author":"Brivio E.","year":"2021","unstructured":"Brivio E.; Locatelli F.; Lopez Y.M.; A phase 1 study of inotuzumab ozogamicin in pediatric relapsed\/refractory acute lymphoblastic leukemia (ITCC-059 study). Blood 2021,137(12),1582-1590","journal-title":"Blood"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"S171","DOI":"10.1016\/j.clml.2015.04.006","volume":"15","author":"Jabbour E.","year":"2015","unstructured":"Jabbour E.; O\u2019Brien S.; Thomas D.; Inotuzumab Ozogamicin (IO) in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients (pts) and as salvage therapy for adult with Relapsed\/Refractory (R\/R) Acute Lymphoblastic Leukemia (ALL). Clin Lymphoma Myeloma Leuk 2015,15,S171","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Current Pediatric Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573396318666220901165247","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/208439\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573396318666220901165247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T07:41:55Z","timestamp":1676533315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/208439\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573396318666220901165247","relation":{},"ISSN":["1573-3963"],"issn-type":[{"value":"1573-3963","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}